Cipla is currently trading at Rs. 640.00, up by 4.80 points or 0.76% from its previous closing of Rs. 635.20 on the BSE.
The scrip opened at Rs. 635.00 and has touched a high and low of Rs. 642.60 and Rs. 633.35 respectively. So far 7182 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 572.00 on 15-Jun-2015.
Last one week high and low of the scrip stood at Rs. 653.50 and Rs. 620.10 respectively. The current market cap of the company is Rs. 51017.70 crore.
The promoters holding in the company stood at 36.79% while Institutions and Non-Institutions held 34.24% and 26.63% respectively.
Cipla has received an approval for transfer of the consumer healthcare business of the company to Cipla Health on a going concern basis by way of a slump sale for a lump sum consideration of Rs 16 crore. The board of directors at their meeting held on December 10, 2015 has approved for the same.
Cipla Health is a newly incorporated subsidiary of the company and was incorporated on August 27, 2015. It will focus its business activities in the consumer healthcare space. The consumer healthcare business to be transferred to Cipla Health includes the scope of the business as approved on July 09, 2015, along with certain additional business.
The amount and percentage of the turnover contributed by the consumer healthcare business of the company for the financial year 2014-15 was Rs 54.28 crore and approximately 0.48% respectively. The net worth of consumer healthcare business of the company as on March 31, 2015 was Rs 7.88 crore contributing 0.07% of the net worth of the company.
The transaction will enable the company to participate in the attractive and growing over-the-counter market. This business requires a specialized FMCG kind of focus, and a separate subsidiary would enable the company to attract the right talent and provide the focus and attention required for this business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
